Ovarian stimulation: Is there a long-term risk for ovarian, breast and endometrial cancer?

Women's Health

Volumn 6, Issue 6, 2010, Pages 831-839

  Lerner Geva, L ^a,b   Rabinovici, J ^b,c   Lunenfeld, B ^d  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

^d BAR ILAN UNIVERSITY   (Israel)

Author keywords

borderline tumors of the ovary; breast cancer; endometrial cancer; ovarian cancer; ovarian stimulation; ovulation induction

Indexed keywords

CLOMIFENE CITRATE;

BREAST CANCER; CANCER INVASION; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG MEGADOSE; ENDOMETRIUM CANCER; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HIGH RISK POPULATION; HUMAN; INFERTILITY THERAPY; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; NULLIPARA; OVARIAN STIMULATION; OVARY CANCER; OVULATION INDUCTION; REVIEW; TREATMENT DURATION;

BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INFERTILITY, FEMALE; OVARIAN NEOPLASMS; OVULATION INDUCTION; RISK FACTORS;

EID: 78649944541     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.67     Document Type: Review

References (86)

1. Mosher WD, Pratt WF: Fecundity and infertility in the United States: incidence and trends. Fertil. Steril. 56, 192-198 (1991).
2. Schenker JG, Laufer N, Weinstein D et al.: Quintuplet pregnancies. Eur. J. Obstet. Gynecol. Reprod. Biol. 10, 257-268 (1980).
3. Hack M, Brish M, Serr DM et al.: Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy. JAMA 220, 1329-1333 (1972).
4. Oelsner G, Menashe Y, Tur-Kaspa I et al.: The role of gonadotropins in the etiology of ectopic pregnancy. Fertil. Steril. 52, 514-516 (1989).
5. Bider D, Menashe Y, Oelsner G et al.: Ovarian hyperstimulation syndrome due to exogenous gonadotropin administration. Acta. Obstet. Gynecol. Scand. 68, 511-514 (1989).
6. Schenker JG, Weinstein D: Ovarian hyperstimulation syndrome: a current survey. Fertil. Steril. 30, 255-268 (1978).
7. Navot D, Relou A, Birkenfeld A et al.: Risk factors and prognostic variables in the ovarianhyperstimulation syndrome. Am. J. Obstet. Gynceol. 159, 210-215 (1988).
8. Johannes CB, Caro JJ, Hartz SC et al.: Adverse effects of ovulatory stimulants: a review. Assis. Reprod. Rev. 3, 68-74 (1993).
9. Schenker JG, Ezra Y: Complications of assisted reproductive techniques. Fertil. Steril. 61, 411-422 (1994).
10. Cetin I, Cozzi V, Antonazzo P: Infertility as a cancer factor- A review. Placenta. 29, S169-S177 (2008).
11. Bamford PN, Steele SJ: Uterine and ovarian carcinoma in a patient receiving gonadotrophin therapy. Case report. Br. J. Obstet. Gynaecol. 89(11), 962-964 (1982).
12. Atlas M, Menczer J: Massive hyperstimulation and borderline carcinoma of the ovary. A possible association. Acta. Obstet. Gynecol. Scand. 61(3), 261-263 (1982).
13. Ben-Hur H, Dgani R, Lancet M et al.: Ovarian carcinoma masquerading as ovarian hyperstimulation syndrome. Acta. Obstet. Gynecol. Scand. 65(7), 813-814 (1986).
14. Carter ME, Joyce DN: Ovarian carcinoma in a patient hyperstimulated by gonadotropin therapy for in vitro fertilization: a case report. J. In. Vitro. Fert. Embryo. Transf. 4(2), 126-128 (1987).
15. Kulkarni R, McGarry JM: Follicular stimulation and ovarian cancer. BMJ 299(6701), 740 (1989).
16. Goldberg GL, Runowicz CD: Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - is there a link? Am. J. Obstet. Gynecol. 166(3), 853-854 (1992).
17. Nijman HW, Burger CW, Baak JP et al.: Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases. Eur. J. Cancer 28A(12), 1971-1973 (1992).
18. Balasch J, Barri PN: Follicular stimulation and ovarian cancer? Hum. Reprod. 8(7), 990-996 (1993).
19. Willemsen W, Kruitwagen R, Bastiaans B et al.: Ovarian stimulation and granulosa-cell tumour. Lancet 341(8851), 986-988 (1993).
20. Karlan BY, Marrs R, Lagasse LD: Advanced-stage ovarian carcinoma presenting during infertility evaluation. Am. J. Obstet. Gynecol. 171(5), 1377-1378 (1994).
21. Komatsu T, Konishi I, Mandai M et al.: Peritoneal papillary serous carcinoma arising in an infertile woman during ovulationinduction therapy: immunohistochemical expression of LH/hCG receptors. Gynecol. Oncol. 56(3), 470-474 (1995).
22. Salle B, de Saint Hilaire P, Devouassoux M et al.: Another two cases of ovarian tumours in women who had undergone multiple ovulation induction cycles. Hum. Reprod. 12(8), 1732-1735 (1997).
23. Unkila-Kallio L, Leminen A, Tiitnen A et al.: Malignant tumors of the ovary or the breast in association with infertility: a report of thirteen cases. Acta. Obstet. Gynecol. Scand. 76(2), 177-181 (1997).
24. Lopes P, Mensier A: Ovarian cancer and assisted reproductive technology. Eur. J. Obstet. Gynecol. Reprod. Biol. 51(3), 171-173 (1993). (Pubitemid 24013705)
25. Grimbizis G, Tarlatzis BC, Bontis J et al.: Two cases of ovarian tumours in women who had undergone multiple ovarian stimulation attempts. Hum. Reprod. 10(3), 520-523 (1995).
26. Fathalla MF: Incessant ovulation - a factor in ovarian neoplasia? Lancet. 2, 163 (1971).
27. Cramer DW, Welch WR: Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J. Natl. Cancer Inst. 71, 717-721 (1983).
28. Brinton L: Long-term effects of ovulationstimulating drugs on cancer risk. Reprod. Biomed. Online 15, 38-44 (2007).
29. Whittemore AS, Harris R, Itnyre J: Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case- control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am. J. Epidemiol. 15(10), 1212-1220 (1992). (Pubitemid 23026892)
30. Shoham Z: Epidemiology, etiology, and fertility drugs in ovarian epithelial carcinoma: where are we today? Fertil. Steril. 62 (3) 433-448 (1994).
31. Ness RB, Cramer DW, Goodman MT et al.: Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am. J. Epidemiol. 155(3), 217-224 (2002).
32. Tworoger SS, Fairfield KM, Colditz GA et al.: Association of oral contraceptive use, other contraceptive methods, and infertility ith ovarian cancer risk. Am. J. Epidemiol. 166(8), 894-901 (2007).
33. Rossing MA, Daling JR, Weiss NS et al.: Ovarian tumors in a cohort of infertile women. N. Engl. J. Med. 331(12), 771-776 (1994).
34. Modan B, Ron E, Lerner-Geva L et al.: Cancer incidence in a cohort of infertile women. Am. J. Epidemiol. 147, 1038-1042 (1998).
35. Doyle P, Maconochie N, Beral V et al.: Cancer incidence following treatment for infertility at a clinic in the UK. Human Reprod. 17, 2209-2213 (2002).
36. Brinton LA, Lamb EJ, Moghissi KS et al.: Ovarian cancer after the use of ovulationstimulating drugs. Obstet. Gynecol. 103 (6), 1194-1203 (2004).
37. Kashyap S, Moher D, Fung M et al.: Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet. Gynecol. 103, 785-794 (2004).
38. Sanner K, Conner P, Bergfeldt K et al.: Ovarian epithelilal neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil. Steril. 91, 1152-1158 (2009).
39. Jensen A, Sharif H, Frederiksen K, Kjaer SK: Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ 338, b249 (2009).
40. Lerner-Geva L, Geva E, Lessing JB et al.: The possible association between in vitro fertilization treatments and cancer development. Int. J. Gynecol. Cancer. 13, 23-27 (2003).
41. Ron E, Lunenfeld B, Menczer J et al.: Cancer incidence in a cohort of infertile women. Am. J. Epidemiol. 125, 780-790 (1987).
42. Harris RE, Namboodiri KK, Wynder EL: Breast cancer risk: effects of estrogen replacement therapy and body mass. J. Natl. Cancer. Inst. 84(20), 1575-1582 (1992).
43. Shushan A, Simon A, Benshushan A et al.: Assisted hatching of in-vitro fertilized human embryos by micromanipulation of the zona pelucida. Harefuah. 125(12), 468-471(1993).
44. Parazzini F, Negri E, La Vecchia C et al.: Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum. Reprod. 12(10), 2159-2161 (1997).
45. Hirsh-Yechezkel G, Chetrit A, Lubin F et al.: Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. Gynecol. Oncol. 89(3), 494-498 (2003).
46. Harding M, Cowen S, Hole D et al.: Estrogen and progesterone receptors in ovarian cancer. Cancer. 65(3), 486-491 (1990).
47. Gotlieb WH, Chetrit A, Menczer J et al.: National Israel Ovarian Cancer Study Group: Demographic and genetic characteristics of patients with borderline ovarian tumors as compared with early stage invasive ovarian cancer. Gynecol. Oncol. 97(3), 780-783 (2005).
48. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (Eds): Cancer Incidence in Five Continents. Age Specific and Age-Standardized Incidence Rates. (Vol. 7). IARC scientific publications No. 143, Lyon, France, 446-742 (1997).
49. Lee E, Ma H, McKean-Cowdin R et al.: Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA 1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol. Biomarkers Prev. 17(11), 3170-3178 (2008).
50. Borini A, Rebellato E: Focus on Breast and Ovarian Cancer. Placenta 29(Suppl. B), 184-190 (2008).
51. Braga C, Negri E, La Vecchia C et al.: Fertility treatment and risk of breast cancer. Hum. Reprod. 11, 300-303 (1996). (Pubitemid 26089178)
52. Burkman RT, Tang MC, Malone K et al.: Infertility and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Womens Contraceptive and Reproductive Experiences Study. Fertil. Steril. 79, 844-854 (2003).
53. Cowan LD, Gordis L, Tonascia JA et al.: Breast cancer incidence in women with a history of progesterone deficiency. Am. J. Epidemiol. 114, 209-217 (1981).
54. Coulam CB, Annegers JF, Kranz JS et al.: Chronic anovulation syndrome and associated neoplasia. Obstet. Gynecol. 61, 403-407 (1983).
55. Potashnik G, Lerner-Geva L, Genkin L et al.: Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil. Steril. 71, 853-859 (1999).
56. Brinton LA, Scoccia B, Moghissi KS et al.: Breast cancer risk associated with ovulationstimulating drugs. Hum. Reprod. 19, 2005-2013 (2004). (Pubitemid 39236465)
57. Calderon-Margalit R, Friedlander Y, Yanetz R et al.: Cancer risk after exposure to treatments for ovulation induction. Am. J. Epidemiol. 169(3), 365-375 (2009).
58. Orgéas CC, Sanner K, Hall P et al.: Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. Am. J. Obstet. Gynecol. 200, 72.e1-7 (2009).
59. Venn A, Watson L, Lumley J et al.: Breast and ovarian cancer incidence after infertility and in-vitro fertilization. Lancet 346, 995-1000 (1995).
60. Venn A, Watson L, Bruinsma F et al.: Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354, 1586-1590 (1999).
61. Dor J, Lerner-Geva L, Rabinovici J et al.: Cancer incidence in a cohort of infertile women treated with in vitro fertilization. Fertil. Steril. 77, 324-327 (2002).
62. Brzezinski A, Peretz T, Mor-Yosef S et al.: Ovarian stimulation and breast cancer: is there a link? Gynecol. Oncol. 52, 292-295 (1994).
63. Pappo I, Lerner-Geva L, Halevy A et al.: The possible association between IVF and breast cancer incidence. Ann. Surg. Oncol. 15(4), 1048-1055 (2008).
64. Kristiansson P, Björ O, Wramsby H: Tumour incidence in Swedish women who gave birth following IVF treatment. Hum. Reprod. 22(2), 421-426 (2007).
65. Kashyap S: Meta-analysis on the possible association between ovulation induction and breast cancer risk. Presented at: 60th Annual Meeting of the American Society for Reproductive Medicine. Philadelphia, PA, USA, 16-20 October (2004).
66. Zreik TG, Mazloom A, Chen Y, et al: Fertility drugs and the risk of breast cancer: a meta-analysis and review. Breast Cancer Res. Treat. (2010) (Epub ahead of print).
67. Brinton LA, Moghissi KS, Scoccia B et al.: Ovulation induction and cancer risk. Fertil. Steril. 83(2), 261-274 (2005).
68. Althuis MD, Moghissi KS, Westhoff CL et al.: Uterine cancer after use of clomiphene citrate to induce ovulation. Am. J. Epidemiol. 161(7), 607-615 (2005).
69. Pillay OC, Te Fong LF, Crow JC et al.: The association between polycystic ovaries and endometrial cancer. Hum. Reprod. 21(4), 924-929 (2006).
70. Wild S, Pierpoint T, Jacobs H et al.: Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum. Fertil. (Camb). 3(2), 101-105 (2000).
71. Papaioannou S, Tzafettas J: Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 24, 19-27 (2010).
72. Benshushan A, Paltiel O, Brzezinski A et al.: Ovulation induction and risk of endometrial cancer: a pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol. 98(1), 53-57 (2001).
73. Shu XO, Brinton LA, Gao YT et al.: Population-based case-control study of ovarian cancer in Shanghai. Cancer Res. 49(13), 3670-3674 (1989).
74. Franceschi S, La Vecchia C, Negri E et al.: Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum. Reprod. 9(9), 1673-1675 (1994).
75. Shushan A, Paltiel O, Iscovich J et al.: Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil. Steril. 65(1), 13-18 (1996).
76. Mosgaard BJ, Lidegaard O, Kjaer SK et al.: Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil. Steril. 67(6), 1005-1012 (1997).
77. Parazzini F, Pelucchi C, Negri E et al.: Use of fertility drugs and risk of ovarian cancer. Hum. Reprod. 16(7), 1372-1375 (2001). (Pubitemid 32640310)
78. Lerner-Geva L. Ovarian stimulation and cancer. Presented at: 14th world congress of Gynecological Endocrinology. Florence, Italy, 4-7 March 2010.
79. Gammon MD, Thompson WD: Infertility and breast cancer: a population-based case-control study. Am. J. Epidemiol. 132(4), 708-716 (1990).
80. Ricci E, Parazzini F, Negri E et al.: Fertility and the risk of breast cancer. Hum. Reprod. 14, 1653-1655 (1999).
81. Brinton LA, Melton LJ III, Malkasian GD et al.: Cancer risk after evaluation for infertility. Am. J. Epidemiol. 129, 712-722 (1989).
82. Rossing MA, Daling JR, Weiss NS et al.: Risk of breast cancer in a cohort of infertile women. Gynecol. Oncol. 60, 3-7 (1996).
83. Gauthier E, Paoletti X, Clavel-Chapelon F, and the E3N Group: Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum. Reprod. 19, 2216-2221 (2004).
84. Terry KL, Willett WC, Rich-Edwards JW et al.: A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch. Intern. Med. 166(22), 2484-2489 (2006).
85. Lerner-Geva L, Keinan-Boker L, Blumstein T et al.: Infertility, ovulation induction treatments and the incidence of breast cancer - a historical prospective cohort of Israeli women. Breast Cancer Res. Treat. 100, 201-212 (2006).
86. Jensen A, Sharif H, Svare EI et al.: Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol. Biomarkers Prev. 16(7), 1400-1407 (2007).